Abstract
Arginine-vasopressin (AVP) immunoreactivity (Ir) has been found to be elevated in platelet-rich plasma. PlatAVP was defined as platelet-rich plasma Ir minus platelet-poor plasma Ir (Pavp). PlatAVP, Pavp, and synthetic AVP were found to have identical retention time on high performance liquid chromatography analysis and similar mobility on thin-layer chromatography. During a standard osmotic suppression-stimulation test, Pavp increased with plasma osmolality (Posm, mosmol/kg H2O); Pavp (pg/ml) = 0.98 (Posm -274.4), r = 0.57, P less than 0.001, n = 65; but PlatAVP was not significantly correlated with Posm and remained at 5 pg/ml. This PlatAVP concentration was estimated to represent a true intraplatelet AVP concentration of 0.4 to 3.7 X 10(-9) M. Binding studies on intact human platelets demonstrated specific binding sites for [3H]AVP (n = 16; BMax = 98 +/- 30 binding sites/platelet; Kd = 0.72 +/- 0.24 nM). This in vitro affinity association constant (Kd) was close to the estimated in vivo intraplatelet AVP concentration. Measurement of PlatAVP could estimate vasopressin bound to a specific platelet receptor.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barberis C. [3H]vasopressin binding to rat hippocampal synaptic plasma membrane. Kinetic and pharmacological characterization. FEBS Lett. 1983 Oct 17;162(2):400–405. doi: 10.1016/0014-5793(83)80795-9. [DOI] [PubMed] [Google Scholar]
- Bichet D. G., Kortas C., Manzini C., Barjon J. N. A specific antibody to vasopressin in a man with concomitant resistance to treatment with Pitressin. Clin Chem. 1986 Jan;32(1 Pt 1):211–212. [PubMed] [Google Scholar]
- Bichet D. G., Kortas C., Mettauer B., Manzini C., Marc-Aurèle J., Rouleau J. L., Schrier R. W. Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure. Kidney Int. 1986 Jun;29(6):1188–1196. doi: 10.1038/ki.1986.126. [DOI] [PubMed] [Google Scholar]
- Chesney C. M., Crofton J. T., Pifer D. D., Brooks D. P., Huch K. M., Share L. Subcellular localization of vasopressin-like material in platelets. J Lab Clin Med. 1985 Sep;106(3):314–318. [PubMed] [Google Scholar]
- Haslam R. J., Rosson G. M. Aggregation of human blood platelets by vasopressin. Am J Physiol. 1972 Oct;223(4):958–967. doi: 10.1152/ajplegacy.1972.223.4.958. [DOI] [PubMed] [Google Scholar]
- Lindeberg G. Separation of vasopressin analogues by reversed-phase high-performance liquid chromatography. J Chromatogr. 1980 May 30;193(3):427–431. doi: 10.1016/s0021-9673(00)87743-2. [DOI] [PubMed] [Google Scholar]
- Robertson G. L., Mahr E. A., Athar S., Sinha T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest. 1973 Sep;52(9):2340–2352. doi: 10.1172/JCI107423. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Thibonnier M., Roberts J. M. Characterization of human platelet vasopressin receptors. J Clin Invest. 1985 Nov;76(5):1857–1864. doi: 10.1172/JCI112179. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vanderwel M., Lum D. S., Haslam R. J. Vasopressin inhibits the adenylate cyclase activity of human platelet particulate fraction through V1-receptors. FEBS Lett. 1983 Dec 12;164(2):340–344. doi: 10.1016/0014-5793(83)80313-5. [DOI] [PubMed] [Google Scholar]
- Vittet D., Rondot A., Cantau B., Launay J. M., Chevillard C. Nature and properties of human platelet vasopressin receptors. Biochem J. 1986 Feb 1;233(3):631–636. doi: 10.1042/bj2330631. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zerbe R. L., Robertson G. L. A comparison of plasma vasopressin measurements with a standard indirect test in the differential diagnosis of polyuria. N Engl J Med. 1981 Dec 24;305(26):1539–1546. doi: 10.1056/NEJM198112243052601. [DOI] [PubMed] [Google Scholar]